FrederickLansiganMD(He/Him)

Cutaneous Lymphoma, Hematologic Oncology

Interim Associate Dean of Diversity, Equity, and Inclusion, Associate Professor, Medicine and Dermatology, Geisel School of Medicine at Dartmouth

Dr. Lansigan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon, NH 03756

Erick Lansigan, MD is an authority on quality improvement and applies this methodology to promoting Diversity, Equity, Inclusion, and Belonging in education, admissions, recruiting, student experience, workforce development, advocacy, and community engagement, as well as clinical research, health systems, and patient care.

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2002 - 2006
State University of New York Downstate Medical Center College of MedicineClass of 2002

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013

PubMed

331 citations
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.
Adam M. Petrich, Mitul Gandhi, Borko Jovanovic, Jorge J. Castillo, Saurabh Rajguru
Blood. 2014-10-09
26 citations
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.
Pallawi Torka, Shalin Kothari, Suchitra Sundaram, Shaoying Li, L. Jeffrey Medeiros
Blood Advances. 2020-01-28
104 citations
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission
Daniel J. Landsburg, Marissa K. Falkiewicz, Joseph Maly, Kristie A. Blum, Christina Howlett
Journal of Clinical Oncology. 2017-05-05

Abstracts/Posters

Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Frederick Lansigan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Identification of FASN-Dependent Onco-Metabolic Regulation of the Pentose Phosphate Pathway (PPP) and Nucleotide Metabolism in Non-Hodgkin Lymphoma (NHL)
Frederick Lansigan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United St...
Frederick Lansigan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Diversity Among Oncologists Has Not Kept Pace with the U.S. PopulationFebruary 17th, 2022
Oncology Academic Departments Slowly Becoming More DiverseDecember 30th, 2021
Lenalidomide plus Rituximab: Effective for Older Patients with R/R Indolent NHLDecember 6th, 2020